Rachel Ngo
Amgen (United States)(US)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Microtubule and mitosis dynamics, Advanced Breast Cancer Therapies, Cancer-related Molecular Pathways, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3(2014)70 cited
- → Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia(2014)34 cited
- → Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers(2025)14 cited
- → From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy(2025)12 cited
- → Development of a time-resolved fluorescence resonance energy transfer assay for cyclin-dependent kinase 4 and identification of its ATP-noncompetitive inhibitors(2011)6 cited
- → Supplementary Figures 1 - 2, Table 1 from Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia(2023)
- → Abstract A279: Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor.(2013)
- → Data from Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia(2023)